EP3113771A4 - Utilisations therapeutiques de l'ibogaïne et composes associes - Google Patents
Utilisations therapeutiques de l'ibogaïne et composes associes Download PDFInfo
- Publication number
- EP3113771A4 EP3113771A4 EP15758129.9A EP15758129A EP3113771A4 EP 3113771 A4 EP3113771 A4 EP 3113771A4 EP 15758129 A EP15758129 A EP 15758129A EP 3113771 A4 EP3113771 A4 EP 3113771A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ibogaine
- related compounds
- therapeutic uses
- therapeutic
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 title 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 title 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947397P | 2014-03-03 | 2014-03-03 | |
| US201461952718P | 2014-03-13 | 2014-03-13 | |
| US201461952736P | 2014-03-13 | 2014-03-13 | |
| US201461952724P | 2014-03-13 | 2014-03-13 | |
| US201461952725P | 2014-03-13 | 2014-03-13 | |
| US201461952740P | 2014-03-13 | 2014-03-13 | |
| US201461952743P | 2014-03-13 | 2014-03-13 | |
| US201462049968P | 2014-09-12 | 2014-09-12 | |
| PCT/US2015/018356 WO2015134405A1 (fr) | 2014-03-03 | 2015-03-02 | Utilisations therapeutiques de l'ibogaïne et composes associes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3113771A1 EP3113771A1 (fr) | 2017-01-11 |
| EP3113771A4 true EP3113771A4 (fr) | 2017-10-25 |
Family
ID=54055765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15758129.9A Withdrawn EP3113771A4 (fr) | 2014-03-03 | 2015-03-02 | Utilisations therapeutiques de l'ibogaïne et composes associes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3113771A4 (fr) |
| AU (2) | AU2015225442A1 (fr) |
| CA (2) | CA3212001A1 (fr) |
| WO (1) | WO2015134405A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
| US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN113993523A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗抑郁症和其他各种病症 |
| US11596638B2 (en) * | 2019-10-01 | 2023-03-07 | Mind Medicine, Inc | 18-MC for treatment of substance use disorders |
| CN115916215A (zh) * | 2020-04-16 | 2023-04-04 | 长矛治疗股份有限公司 | 迷幻剂衍生物的经皮微剂量递送 |
| US20220409628A1 (en) * | 2021-06-29 | 2022-12-29 | Mind Medicine, Inc. | 18-mc for treating obesity |
| EP4398893A4 (fr) * | 2021-09-10 | 2025-07-16 | ATAI Life Sciences AG | Polythérapie par ibogaïne |
| CN120916770A (zh) * | 2023-02-15 | 2025-11-07 | 克力迈实验室公司 | 任选地与n-酰基乙醇胺组合地包含伊博格碱的组合物及其用途 |
| WO2024254701A1 (fr) * | 2023-06-16 | 2024-12-19 | Ambio Life Sciences Inc. | Ibogaïne pour le traitement de la sclérose en plaques |
| WO2025000092A1 (fr) * | 2023-06-28 | 2025-01-02 | Ambio Life Sciences Inc. | Traitement à base d'ibogaïne |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857523A (en) * | 1988-07-18 | 1989-08-15 | Nda International, Inc. | Rapid method for attenuating the alcohol dependency syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629307A (en) * | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| WO2008039179A1 (fr) * | 2006-09-26 | 2008-04-03 | Addiction Research Institute, Inc. | Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c |
-
2015
- 2015-03-02 AU AU2015225442A patent/AU2015225442A1/en not_active Abandoned
- 2015-03-02 WO PCT/US2015/018356 patent/WO2015134405A1/fr not_active Ceased
- 2015-03-02 CA CA3212001A patent/CA3212001A1/fr active Pending
- 2015-03-02 CA CA2978537A patent/CA2978537C/fr active Active
- 2015-03-02 EP EP15758129.9A patent/EP3113771A4/fr not_active Withdrawn
-
2020
- 2020-11-18 AU AU2020273281A patent/AU2020273281B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857523A (en) * | 1988-07-18 | 1989-08-15 | Nda International, Inc. | Rapid method for attenuating the alcohol dependency syndrome |
Non-Patent Citations (5)
| Title |
|---|
| AMIR H. REZVANI ET AL: "Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR., vol. 52, no. 3, 1 November 1995 (1995-11-01), US, pages 615 - 620, XP055223408, ISSN: 0091-3057, DOI: 10.1016/0091-3057(95)00152-M * |
| DEBORAH C. MASH ET AL: "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 914, no. 1, 1 September 2000 (2000-09-01), US, pages 394 - 401, XP055407277, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2000.tb05213.x * |
| JONATHAN CACHAT ET AL: "Unique and potent effects of acute ibogaine on zebrafish: The developing utility of novel aquatic models for hallucinogenic drug research", BEHAVIOURAL BRAIN RESEARCH., vol. 236, 1 January 2013 (2013-01-01), NL, pages 258 - 269, XP055407280, ISSN: 0166-4328, DOI: 10.1016/j.bbr.2012.08.041 * |
| KENNETH R. ALPER ET AL: "Treatment of Acute Opioid Withdrawal with Ibogaine", AMERICAN JOURNAL OF ADDICTIONS, vol. 8, no. 3, 1 January 1999 (1999-01-01), US, pages 234 - 242, XP055223410, ISSN: 1055-0496, DOI: 10.1080/105504999305848 * |
| KOENIG XAVER ET AL: "Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 273, no. 2, 22 May 2013 (2013-05-22), pages 259 - 268, XP028784922, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.05.012 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2978537A1 (fr) | 2015-09-11 |
| CA3212001A1 (fr) | 2015-09-11 |
| EP3113771A1 (fr) | 2017-01-11 |
| AU2020273281A1 (en) | 2020-12-17 |
| AU2015225442A1 (en) | 2016-10-20 |
| CA2978537C (fr) | 2023-10-24 |
| AU2020273281B2 (en) | 2024-05-02 |
| WO2015134405A1 (fr) | 2015-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3204360A4 (fr) | Composés thérapeutiques et leurs utilisations | |
| EP3377070A4 (fr) | Composés et leurs méthodes d'utilisation | |
| EP3245291A4 (fr) | Nouvelles micro-dystrophines et méthodes d'utilisation associées | |
| EP3218005A4 (fr) | Composés interagissant avec le glycane et procédés d'utilisation | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| EP3113771A4 (fr) | Utilisations therapeutiques de l'ibogaïne et composes associes | |
| EP3102200A4 (fr) | Composés et compositions thérapeutiques | |
| EP3116511A4 (fr) | Compositions de composés sélénoorganiques et leurs procédés d'utilisation correspondants | |
| EP3116898A4 (fr) | Utilisation de la protéine m013 exprimée par un vecteur aav comme agent thérapeutique anti-inflammatoire | |
| EP3134088A4 (fr) | Composés pyrazolone bicycliques et procédés d'utilisation | |
| EP3188721A4 (fr) | Agents thérapeutiques humains | |
| EP3117827A4 (fr) | Composition vaginale et son utilisation | |
| EP3190886A4 (fr) | Compositions et méthodes d'utilisation de ces compositions | |
| EP3107546A4 (fr) | Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés | |
| EP3297619A4 (fr) | Utilisations thérapeutiques de la l-4-chlorocynurénine | |
| EP3231793A4 (fr) | Composés de dihydropyrimidine-2-one et leurs utilisations médicales | |
| EP3229813A4 (fr) | Traitement d'une l'inflammation médiée par hmgb1 | |
| EP3384921A4 (fr) | Nouvelle utilisation de la thiopeptine | |
| EP3119199A4 (fr) | Composés et procédés d'utilisation desdits composés | |
| EP3151862A4 (fr) | Compositions de détoxification thérapeutique et procédés de fabrication et d'utilisation de celles-ci | |
| EP3197470A4 (fr) | Cis-gnetin h et trans-gnetin h en tant qu'agents thérapeutiques | |
| EP3207029A4 (fr) | Compositions de tryptamideet procédés d'utilisation | |
| EP3145525A4 (fr) | Utilisation de microperoxidases pour le traitement de la carboxyhémoglobinémie | |
| EP3204003A4 (fr) | Sélénosucres et leurs utilisations thérapeutiques | |
| PL3143032T3 (pl) | Nowe pochodne oksazafosforyn i ich zastosowania terapeutyczne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20161003 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170926 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/32 20060101ALI20170920BHEP Ipc: A61K 31/404 20060101ALI20170920BHEP Ipc: A61P 25/34 20060101ALI20170920BHEP Ipc: A61P 25/36 20060101ALI20170920BHEP Ipc: A61K 31/55 20060101AFI20170920BHEP Ipc: A61P 25/30 20060101ALI20170920BHEP Ipc: A61K 31/4738 20060101ALI20170920BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180424 |